TYME Inc., an emerging biotechnology company, develops cancer metabolism-based therapies (CMBTs™) that aim to target a broad range of solid tumors and hematologic cancers. CMBTs take advantage of a cancer cell’s unique innate metabolic characteristics to induce cancer cell death while simultaneously maintaining the patients’ quality of life as a concurrent clinical endpoint. Specifically, SM88, the lead asset, is a dysfunctional Tyrosine designed to arrest the cancer cell’s protein synthesis thereby stimulating ROS production, increasing oxidative stress and resulting in apoptosis.
Additional Info
Will your company display a new product or promote a new indication/enhanced feature(s) for an existing product in your booth?
No